Exacerbation rate
| Non-OCS dependent | OCS dependent | |||
|---|---|---|---|---|
| Placebo (n=110) | Mepolizumab (n=318) | Placebo (n=45) | Mepolizumab (n=143) | |
| Exacerbation rate/year | 1.90 | 1.07 | 3.12 | 1.54 |
| Rate ratio (95% CI) | 0.56 (0.42 to 0.76) | 0.49 (0.35 to 0.70) | ||
| Interaction p value | 0.503 | |||
OCS, oral corticosteroids.